48,833
edits
Line 331: | Line 331: | ||
#* VHL gene mutation. | #* VHL gene mutation. | ||
#* Clear cell RCC. | #* Clear cell RCC. | ||
# Hereditary clear cell carcinoma. | # Hereditary [[clear cell renal cell carcinoma]]. | ||
#* VHL gene mutation. | #* VHL gene mutation. | ||
# Hereditary papillary carcinoma | # Hereditary [[papillary renal cell carcinoma]]. | ||
#* MET proto-oncogene mutation. | #* MET proto-oncogene mutation. | ||
#* PaRCC type 1.<ref name=Ref_WMSP290>{{Ref WMSP|290}}</ref> | #* PaRCC type 1.<ref name=Ref_WMSP290>{{Ref WMSP|290}}</ref> | ||
Line 339: | Line 339: | ||
#* FH (fumarate hydratase) gene mutation.<ref name=omim136850>{{OMIM|136850}}</ref> | #* FH (fumarate hydratase) gene mutation.<ref name=omim136850>{{OMIM|136850}}</ref> | ||
#* PaRCC type 2. | #* PaRCC type 2. | ||
#* Benign | #* Benign [[leiomyoma]]s skin/[[uterine leiomyoma|uterus]]. | ||
#* Uterine [[leiomyosarcoma]]. | #* Uterine [[leiomyosarcoma]]. | ||
# Birt–Hogg–Dubé syndrome:<ref name=Ref_WMSP290>{{Ref WMSP|290}}</ref> | # Birt–Hogg–Dubé syndrome:<ref name=Ref_WMSP290>{{Ref WMSP|290}}</ref> |
edits